Vessix is based in California, USA. Vessix Renal denervation is an emerging, minimally-invasive, catheter-based approach to treat uncontrolled hypertension. Vessix had been acquired by Boston Scientific Corporation.

PINS  Medical was founded in 2008, headquartered in Beijing. The company is a high-tech enterprise specializing in the research and development, production and sales of serial neuroregulatory products such as cerebral pacemaker, vagus nerve stimulator, spinal cord stimulator, sacral nerve stimulator, and is committed to providing advanced treatment for patients with Parkinson's disease, epilepsy, pain, urinary incontinence and other functional neurological diseases.
As a component unit of "National Engineering Research Center of Neuroregulation", it has established a collaborative innovation model of "production, study, research and medicine" in close cooperation with Tsinghua University and many clinical hospitals. Since its establishment, the company has undertaken a number of national key research and development programs, national science and technology support programs, Beijing major science and technology special programs and other projects. It has obtained a series of registration certificates of cerebral pacemakers, vagus nerve stimulators, sacral nerve stimulators and spinal nerve stimulators and sold them on the market, breaking the monopoly of American companies in the field of neural regulation products.

PINS  Medical was founded in 2008, headquartered in Beijing. The company is a high-tech enterprise specializing in the research and development, production and sales of serial neuroregulatory products such as cerebral

Hinova is one of the fastest growing start-up drug discovery and development companies in China. Currently Hinova have one new anti-prostate cancer drug being developed in Phase III of the international multi-center trials, an anti-hyperuricemia and gout drug being developed in Phase I clinical trials in China, as well as several other projects in the stages of IND enabling studies and drug discovery. Hinova endeavor to deliver novel therapies to patients worldwide.

Xuanzhu Biology was established in 2002 with a registered capital of 100 million yuan, mainly engaged in the research and development of new molecular solid drugs. Since its establishment, the company has invested more than 2 billion yuan in the field of innovative drugs. At present, the company has formed a complete new drug research and development system, with a professional platform from new drug structure design, evaluation, candidate compound establishment, clinical research, and new drug application. The company has passed the intellectual property management system certification, ISO9001 quality management system certification, in the domestic drug research and development in the leading level, and is committed to building a world-class innovative drug research platform.

Geneseeq established in 2008, is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine.Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

Sinovation is a leading company developing intelligent surgery platform for minimally invasive precision treatment in neurosurgery in China. Through a full range of intracranial electrodes, surgical navigation and positioning system, and intracranial laser ablation treatment system, the company covers the whole process solutions of neurosurgery diagnosis, preoperative planning, intraoperative navigation and positioning, real-time monitoring and treatment from top hospitals to primary hospitals, meeting the needs of minimally invasive and craniotomy for a variety of intracranial diseases such as epilepsy, glioma, brain metastasis, and cerebral hemorrhage.
The company adheres to the collaborative development of equipment and consumables. At present, 8 products have obtained the NMPA Class III medical device registration certificate, among which the market share of intracranial electrode reaches 90%, and the domestic market share of neurosurgical robot is the first. Self-developed the first domestic magnetic resonance guided laser ablation system (LITT) will soon be approved for market, and more than ten devices and high-value consumables are under continuous research and development.

Surgerii Robot is a high-tech enterprise committed to completely independent research and development, production and sales of single/porous universal minimally invasive endoscopic surgical robot system. The single-hole endoscopic surgery robot developed by the company is the first similar product to pass the green channel of review and approval of innovative medical devices in China. Currently, it has completed clinical trials in urology surgery and is expected to be approved for market in the first half of 2023. Meanwhile, clinical trials in gynecology, general surgery and thoracic surgery are being carried out simultaneously in Union Medical College Hospital, Ruijin Hospital and Shanghai Chest Hospital. Relying on the innovative design of "dual continuum mechanism", the high-performance deformable surgical arm carried by the company is flexible and accurate, and the comprehensive performance is comparable to the international top single-hole surgical robot, and breaks the foreign technology monopoly for many years in one stroke. At present, the company has obtained 169 authorized patents and established a very high technical barrier.
 

Chengdu Tianrui  Xingtong Technology Co., LTD., founded in 2013, is a private high-tech enterprise focusing on microwave, millimeter wave active phased array chip and antenna.

After years of efforts and experience accumulation, Tianriestong has the ability of independent design, research and development, production and service of the whole chain of chip - module - antenna - whole solution - test, and has become one of the most complete enterprises in the industry.